S

Sanofi

Global pharma company; vaccines and R&D

North America Medical Head - General Medicines

Full-TimeDeadline 12/18/26
$293.3k - $423.6k
Expert
PhD, MD
Morristown, NJ, USA
Hybrid
Biology & Biotech

About the job

Requirements
  • A minimum of 10 years of job-related experience.
  • A strong track record in developing and executing medical strategy in the United States and leading a sizable medical affairs function.
  • A demonstrated track record of building and maintaining a key opinion leader network in the United States and Canada.
  • Experience working across and building effective partnerships among Research and Development, Commercial, Medical, Safety, and Regulatory functions.
  • A strong understanding of the healthcare landscape.
  • Experience working within an international company with a complex organizational environment and the ability to operate in a matrix.
  • Experience deploying digital enablers in Medical Affairs.
  • Significant leadership experience and a proven ability to influence and impact key stakeholders.
  • Strong business acumen.
  • Innovative thinking.
  • A collaborative and open-minded approach.
  • Strong interpersonal and influencing skills, including the ability to create and articulate an inspiring organizational vision and engage teams in the journey.
  • The ability to positively influence peers, senior leaders, key external stakeholders, and internal partners.
  • The ability to take calculated risks and make bold decisions.
  • High energy, motivation, drive, the ability to think and contribute beyond functional expertise, and an entrepreneurial spirit.
  • Strategic thinking.
  • Customer and patient orientation.
  • High standards of integrity.
  • The ability to build an environment that enables the company culture by encouraging the team to stretch and do things differently, acting for patients and customers, and taking action with humility and a One Sanofi perspective.
Responsibilities
  • Define and champion a patient-centric vision for Medical in General Medicines North America, aligned with global strategy and local business priorities.
  • Provide strategic leadership for the medical function, partnering with Commercial, Access, and Research and Development teams to co-create integrated plans that ensure scientific rigor and measurable patient outcomes.
  • Represent Medical on the North America Leadership Team, contribute to enterprise-wide decisions, and shape overall business direction.
  • Lead, inspire, and develop a high-performing medical team of approximately 100 professionals, build a strong talent pipeline, and foster scientific excellence and continuous learning.
  • Establish and enforce ethical standards across medical activities and serve as a role model for proactive compliance and quality management.
  • Ensure medical governance, including oversight of marketing activities such as symposia, scientific communications, and promotional materials within a patient-centered risk-benefit framework.
  • Lead the effective and timely resolution of compliance issues and ensure adherence to applicable regulations and company policies.
  • Lead Medical Affairs activities across pre-launch, launch, and post-launch phases, ensuring lifecycle management for General Medicines products.
  • Partner with Research, Clinical Development, Commercial, Health Economics, Value and Access, and Product Management to deliver integrated, evidence-based strategies that support product differentiation and patient access.
  • Manage the North America medical budget and allocate resources strategically for high-priority medical initiatives.
  • Identify synergies across General Medicines and cross-GBU levels and propose efficient investment strategies to maximize medical and business impact.
  • Build and sustain a network of key opinion leaders, scientific experts, patient advocacy groups, and health authorities to reinforce scientific leadership and strategic positioning.
  • Elevate the company's presence and reputation in the United States medical community through thought leadership, scientific exchange, and engagement on issues shaping the healthcare landscape.
  • Represent the company at major scientific congresses, health authority meetings, and industry forums.
  • Champion deployment of artificial intelligence, digital health tools, and advanced analytics to enhance medical decision-making, evidence generation, and patient outcomes.
  • Drive innovation in integrated care models and Real-World Evidence strategies.
Desired Qualifications
  • An MD.
  • A Ph.D. and publications.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...